SILVERARC CAPITAL MANAGEMENT, LLC

Position in ASND — Ascendis Pharma A/S

CIK 1816307 BOSTON, MA

Position in ASND

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$55,006,732

+$26,493,708 QoQ

Shares Held

206,234

+65.4% QoQ

Ownership

0.314%

of shares outstanding

% of Portfolio

6.12%

of 13F equity value

Holder Rank

#42

of 308 holders

Holding Since

Dec 2020

14 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

SILVERARC CAPITAL MANAGEMENT, LLC holds $802,586,993 across 53 Biotechnology names. ASND ranks #1 (6.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S This page	206,234	$55,006,732
2	CELC	Celcuity Inc.	500,996	$52,414,201
3	COGT	Cogent Biosciences, Inc.	1,280,707	$49,563,360
4	URGN	UroGen Pharma Ltd.	1,301,979	$47,912,827
5	IMNM	Immunome Inc.	2,017,009	$42,740,420
6	DNTH	Dianthus Therapeutics, Inc. /DE/	390,000	$38,017,200
7	RYTM	Rhythm Pharmaceuticals, Inc.	311,461	$34,581,514
8	ORKA	Oruka Therapeutics, Inc.	352,802	$33,576,166

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$55,006,732	206,234	+65.4%	Shares	Sole	2026-08-13
2026-03-31	$28,513,024	124,658	+153.2%	Shares	Sole	2026-05-14
2025-12-31	$10,497,378	49,228	-8.1%	Shares	Sole	2026-02-12
2025-09-30	$10,647,070	53,554	-38.1%	Shares	Sole	2025-11-12
2025-06-30	$14,938,875	86,552	+14.3%	Shares	Sole	2025-08-14
2025-03-31	$11,806,550	75,751	+47.1%	Shares	Sole	2025-05-14
2024-12-31	$7,088,765	51,491	+929.8%	Shares	Sole	2025-02-14
2024-09-30	$746,550	5,000	-78.4%	Shares	Sole	2024-11-14
2022-12-31	$2,827,431	23,151	+363.0%	Shares	Sole	2023-02-14
2022-09-30	$516,300	5,000	-80.0%	Shares	Sole	2022-10-28
2022-03-31	$2,934,000	25,000	+346.5%	Shares	Sole	2022-05-13
2021-06-30	$736,548	5,599	-70.0%	Shares	Sole	2021-08-16
2021-03-31	$2,409,282	18,694	+6.5%	Shares	Sole	2021-05-18
2020-12-31	$2,927,989	17,556	—	Shares	Sole	2021-02-16
No filing history on record for this holder in this stock.